Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo Ward, Chiba 260-8670, Japan.
World J Gastroenterol. 2017 Oct 21;23(39):7110-7118. doi: 10.3748/wjg.v23.i39.7110.
To evaluate the short- and long-term results of endoscopic ultrasound-guided transmural drainage (EUS-GTD) for pancreatic fluid collection (PFC) and identify the predictive factors of treatment outcome for walled-off necrosis (WON) managed by EUS-GTD alone.
We investigated 103 consecutive patients with PFC who underwent EUS-GTD between September 1999 and August 2015. Patients were divided into four groups as follows: WON ( = 40), pancreatic pseudocyst (PPC; = 11), chronic pseudocyst ( = 33), and others ( = 19). We evaluated the short- and long-term outcomes of the treatment. In cases of WON, multiple logistic regression analyses were performed to identify the predictor variables associated with the treatment success. In addition, PFC recurrence was examined in patients followed up for more than 6 mo and internal stent removal after successful EUS-GTD was confirmed.
In this study, the total technical success rate was 96.1%. The treatment success rate of WON, PPC, chronic pseudocyst, and others was 57.5%, 90.9%, 91.0%, and 89.5%, respectively. Contrast-enhanced computed tomography using the multivariate logistic regression analysis revealed that the treatment success rate of WON was significantly lower in patients with more than 50% pancreatic parenchymal necrosis (OR = 17.0; 95%CI: 1.9-150.7; = 0.011) and in patients with more than 150 mm of PFC (OR = 27.9; 95%CI: 3.4-227.7; = 0.002).The recurrence of PFC in the long term was 13.3% (median observation time, 38.8 mo). Mean amylase level in the cavity was significantly higher in the recurrence group than in the no recurrence group ( = 0.02).
The reduction of WON by EUS-GTD alone was associated with the proportion of necrotic tissue and extent of the cavity. The amylase level in the cavity may be a predictive factor for recurrence of PFC.
评估内镜超声引导下经壁引流(EUS-GTD)治疗胰腺液体积聚(PFC)的短期和长期疗效,并确定单独行 EUS-GTD 治疗包裹性坏死(WON)的治疗效果的预测因素。
我们调查了 1999 年 9 月至 2015 年 8 月期间 103 例接受 EUS-GTD 治疗的 PFC 患者。患者分为以下四组:WON(n=40)、胰腺假性囊肿(PPC;n=11)、慢性假性囊肿(n=33)和其他(n=19)。我们评估了治疗的短期和长期结果。对于 WON 患者,采用多变量逻辑回归分析确定与治疗成功相关的预测变量。此外,对随访时间超过 6 个月的患者进行了 PFC 复发检查,并在确认 EUS-GTD 成功后取出内部支架。
本研究的总技术成功率为 96.1%。WON、PPC、慢性假性囊肿和其他的治疗成功率分别为 57.5%、90.9%、91.0%和 89.5%。多变量逻辑回归分析显示,WON 患者的胰腺实质坏死比例>50%(OR=17.0;95%CI:1.9-150.7;P=0.011)和 PFC 直径>150mm(OR=27.9;95%CI:3.4-227.7;P=0.002)的患者治疗成功率明显较低。长期 PFC 复发率为 13.3%(中位观察时间 38.8 个月)。复发组患者囊腔中的平均淀粉酶水平明显高于无复发组(P=0.02)。
EUS-GTD 单独缩小 WON 与坏死组织的比例和囊腔的大小有关。囊腔中的淀粉酶水平可能是 PFC 复发的预测因素。